Abstract nr
Sarcoma: Soft Tissue
Proffered Paper Session: Sarcoma: Soft Tissue and Bone
Chair: J.Y. Blay (France)
Chair: S. Bonvalot (France)
10:30
3400
Management of Desmoid Tumours (DT): A nationwide survey after labeling of 2 expert networks (RRePS and NetSarc)
Speaker: N. Penel (France)
10:45
3401
Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study
Speaker: V. Grünwald (Germany)
11:00
3402
Time interval (TI) between surgery and start of adjuvant radiotherapy (RT): A retrospective analysis of 1150 cases from the French Sarcoma Group
Speaker: J. Fourquet (France)
11:15
Discussant : R. Haas (Netherlands)
11:25
3403
Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS)
Speaker: S. Patel (USA)
11:40
3404
External validation of a nomogram predicting disease-free (DFS) and overall survival (OS) in patients (pts) with primary retroperitoneal sarcoma (pRPS)
Speaker: C. Raut (USA)
11:55
3405
The role of pharmacogenetics in osteosarcoma
Speaker: M. Hagleitner (Netherlands)
12:10
Discussant : S. Sandrucci (Italy)
12:20
13LBA
LATE BREAKING ABSTRACT: Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study
Speaker: R.D. Issels (Germany)
12:30
Discussant : J.Y. Blay (France)